HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 11/27/2012 -- Oclaro Inc. (NASDAQ:OCLR) has plans to sell two of its business lines for $27 million total, the optical communications company said Monday. The company said it will sell its Santa Rosa thin film filter business to Photop Technologies Inc., which is a subsidiary of II-VI Inc. The company will also sell its interleaver product line, which sells fiber-optic devices, to Photop Koncent Inc., another II-VI subsidiary. Oclaro said the deals are part of its broader strategy to focus on its core business. The company plans to use the proceeds to improve its balance sheet and give it some operating flexibility.The company said the $27 million cash deal will be paid in portions — $23 million upon closing, $3 million by Dec. 28 and $1 million in escrow until Dec. 31. Oclaro said selling these product lines will reduce its revenue for the fiscal quarter ending in December by $2 million from what the company had forecast. Analysts expect the company to post quarterly revenue of $155.7 million, according to a survey by FactSet.
Should Investors Buy OCLR Now? Get Our Free Trend Analysis Here
The clinical-stage pharmaceutical firm EntreMed’s (NASDAQ:ENMD) shares gained almost 25 percent on the day, as a release reported the publication of favorable results from a preclinical evaluation in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. The company is developing targeted therapeutics for the treatment of cancer. Shares of EntreMed, Inc. (NCM:ENMD) are trading at $1.73 and is +5.41% from its 50-day Moving Average price of $1.6412 and -7.60% from its 200-day Moving Average price of $1.8722. The average trading volume is 35552 shares and its market capitalization is $21.0M.
How Should Investors React to ENMD Now? Find Out Here
Celsion (Nasdaq:CLSN) led the sector higher today, closing with an impressive 17% gain. The catalyst wasn't the usual fare that can create sudden pops -- a press release or trial results, for instance -- but instead a bullish article posted on financial website Seeking Alpha. Celsion's claim to fame is ThermoDox, a drug based on the company's Lysolipid Thermally Sensitive Liposomes (LTSL) platform being tested in a variety of cancers. This Seeking Alpha article focused on why, if trial results for ThermoDox in liver cancer are good, the stock will be off to the races. The results won't be released until early next year, so consider this the beginning of the speculative fury, with things only intensifying into January. Shares of Celsion Corporati (NCM:CLSN) are trading at $7.80 and is +53.75% from its 50-day Moving Average price of $5.0733 and +99.14% from its 200-day Moving Average price of $3.9168. The average trading volume is 1063650 shares and its market capitalization is $273.1M.
Collect The Full Research Report On CLSN For Free: CLICK HERE
Impac Mortgage Holdings Inc. (NYSEAMEX:IMH) said Monday it has no comment on "unusual trading activity" that saw the company's share price rise 15 percent. The Irvine, Calif., company said the New York Stock Exchange informed it about the trading activity and asked it to make a statement. Impac said it has no comment on any market rumors or speculation related to the trades. On Monday the company's shares jumped $1.88, or 15.3 percent, to $14.21. Volume of just 304,000 shares was about 24 percent higher than normal trading, according to FactSet. Impac Mortgage Ho (AMEX:IMH) is very active today and traded between $12.3501 - 14.47 with total traded volume of 305489 shares. At a current price of 14.21, IMH is +1.88 - +15.25% from the previous close of $12.33. Moreover, At Current Market Price, IMH is in distance of +15.29% from its 50-day Moving Average price of $12.3255 and +142.81% from its 200-day Moving Average price of $5.8523.
Is IMH Chart Position Shows The Buy Signal : Get Free Analyst Research
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)